158 related articles for article (PubMed ID: 34638277)
1. HER3 PET Imaging:
Rinne SS; Leitao CD; Abouzayed A; Vorobyeva A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638277
[TBL] [Abstract][Full Text] [Related]
2. Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.
Rinne SS; Dahlsson Leitao C; Saleh-Nihad Z; Mitran B; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183096
[TBL] [Abstract][Full Text] [Related]
3. Increase in negative charge of
Rinne SS; Dahlsson Leitao C; Gentry J; Mitran B; Abouzayed A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Nov; 9(1):17710. PubMed ID: 31776413
[TBL] [Abstract][Full Text] [Related]
4. Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of
Dahlsson Leitao C; Rinne SS; Mitran B; Vorobyeva A; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30832342
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of [
Oroujeni M; Garousi J; Andersson KG; Löfblom J; Mitran B; Orlova A; Tolmachev V
Cells; 2018 Sep; 7(9):. PubMed ID: 30231504
[TBL] [Abstract][Full Text] [Related]
6. Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules.
Rinne SS; Xu T; Dahlsson Leitao C; Ståhl S; Löfblom J; Orlova A; Tolmachev V; Vorobyeva A
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075258
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model.
Leitao CD; Rinne SS; Altai M; Vorontsova O; Dunås F; Jonasson P; Tolmachev V; Löfblom J; Ståhl S; Orlova A
Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32545760
[TBL] [Abstract][Full Text] [Related]
8. Cyclic versus Noncyclic Chelating Scaffold for
Summer D; Garousi J; Oroujeni M; Mitran B; Andersson KG; Vorobyeva A; Löfblom J; Orlova A; Tolmachev V; Decristoforo C
Mol Pharm; 2018 Jan; 15(1):175-185. PubMed ID: 29160082
[TBL] [Abstract][Full Text] [Related]
9. Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule.
Cai H; Shi Q; Tang Y; Chen L; Chen Y; Tao Z; Yang H; Xie F; Wu X; Liu N; Yang Y; Wu H; Tian R; Lu X; Li L
Mol Pharm; 2019 May; 16(5):1950-1957. PubMed ID: 30986347
[TBL] [Abstract][Full Text] [Related]
10. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.
Orlova A; Bass TZ; Rinne SS; Leitao CD; Rosestedt M; Atterby C; Gudmundsdotter L; Frejd FY; Löfblom J; Tolmachev V; Ståhl S
Mol Pharm; 2018 Aug; 15(8):3394-3403. PubMed ID: 29995421
[TBL] [Abstract][Full Text] [Related]
12. Site-specifically labeled
Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
[TBL] [Abstract][Full Text] [Related]
13. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
14. Affibody-mediated PET imaging of HER3 expression in malignant tumours.
Rosestedt M; Andersson KG; Mitran B; Tolmachev V; Löfblom J; Orlova A; Ståhl S
Sci Rep; 2015 Oct; 5():15226. PubMed ID: 26477646
[TBL] [Abstract][Full Text] [Related]
15. PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.
Garousi J; Andersson KG; Mitran B; Pichl ML; Ståhl S; Orlova A; Löfblom J; Tolmachev V
Int J Oncol; 2016 Apr; 48(4):1325-32. PubMed ID: 26847636
[TBL] [Abstract][Full Text] [Related]
16. ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116.
Terwisscha van Scheltinga AG; Lub-de Hooge MN; Abiraj K; Schröder CP; Pot L; Bossenmaier B; Thomas M; Hölzlwimmer G; Friess T; Kosterink JG; de Vries EG
MAbs; 2014; 6(4):1051-8. PubMed ID: 24870719
[TBL] [Abstract][Full Text] [Related]
17. Performance of nanoScan PET/CT and PET/MR for quantitative imaging of
Chomet M; Schreurs M; Vos R; Verlaan M; Kooijman EJ; Poot AJ; Boellaard R; Windhorst AD; van Dongen GA; Vugts DJ; Huisman MC; Beaino W
EJNMMI Res; 2021 Jun; 11(1):57. PubMed ID: 34117946
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression.
Rosestedt M; Andersson KG; Mitran B; Rinne SS; Tolmachev V; Löfblom J; Orlova A; Ståhl S
Int J Oncol; 2017 Dec; 51(6):1765-1774. PubMed ID: 29039474
[TBL] [Abstract][Full Text] [Related]
19. Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using (
Varasteh Z; De Rose F; Mohanta S; Li Y; Zhang X; Miritsch B; Scafetta G; Yin C; Sager HB; Glasl S; Gorpas D; Habenicht AJR; Ntziachristos V; Weber WA; Bartolazzi A; Schwaiger M; D'Alessandria C
Theranostics; 2021; 11(4):1864-1876. PubMed ID: 33408786
[No Abstract] [Full Text] [Related]
20. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
